Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer.

Cyclin D1 (Ccnd1) is a proto-oncogen amplified in many different cancers and nuclear accumulation of Ccnd1 is a characteristic of tumor cells. Ccnd1 activates the transcription of a large set of genes involved in cell cycle progress and proliferation. However, Ccnd1 also targets cytoplasmic proteins involved in the regulation of cell migration and invasion. In this work, we have analyzed by immunohistochemistry the localization of Ccnd1 in endometrial, breast, prostate and colon carcinomas with different types of invasion. The number of cells displaying membranous or cytoplasmic Ccnd1 was significantly higher in peripheral cells than in inner cells in both collective and pushing invasion patterns of endometrial carcinoma, and in collective invasion pattern of colon carcinoma. Also, the cytoplasmic localization of Ccnd1 was higher when tumors infiltrated as single cells, budding or small clusters of cells. To evaluate cytoplasmic function of cyclin D1, we have built a variant (Ccnd1-CAAX) that remains attached to the cell membrane therefore sequestering this cyclin in the cytoplasm. Tumor cells harboring Ccnd1-CAAX showed high levels of invasiveness and metastatic potential compared to those containing the wild type allele of Ccnd1. However, Ccnd1-CAAX expression did not alter proliferative rates of tumor cells. We hypothesize that the role of Ccnd1 in the cytoplasm is mainly associated with the invasive capability of tumor cells. Moreover, we propose that subcellular localization of Ccnd1 is an interesting guideline to measure cancer outcome.

Oncotarget. 2016 Apr 20 [Epub ahead of print]

Noel P Fusté, Esmeralda Castelblanco, Isidre Felip, Maria Santacana, Rita Fernández-Hernández, Sònia Gatius, Neus Pedraza, Judit Pallarés, Tània Cemeli, Joan Valls, Marc Tarres, Francisco Ferrezuelo, Xavier Dolcet, Xavier Matias-Guiu, Eloi Garí

Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Biostatistics and Epidemiology Unit of the Institut de Recerca Biomèdica de Lleida (IRBLLEIDA), Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Oncological Pathology, Lleida, Catalonia, Spain., Department of Cell Cycle, Lleida, Catalonia, Spain.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe